Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer

被引:51
作者
Bollschweiler, Elfriede [1 ]
Hoelscher, Arnulf H. [1 ]
Metzger, Ralf [1 ,2 ]
机构
[1] Univ Cologne, Dept Gen Visceral & Canc Surg, D-50937 Cologne, Germany
[2] Univ Hosp Cologne, CIO, Cologne, Germany
关键词
adenocarcinomo; esophagus; neoadjuvant chemoradiation; pathologic complete response; regression grading; squamous cell carcinoma; SQUAMOUS-CELL CARCINOMA; RANDOMIZED CONTROLLED-TRIALS; RADIATION-THERAPY; CHEMORADIATION THERAPY; PHASE-II; PREOPERATIVE CHEMORADIOTHERAPY; GASTROESOPHAGEAL JUNCTION; PATHOLOGICAL RESPONSE; ENDOSCOPIC ULTRASOUND; RESECTABLE CANCER;
D O I
10.2217/FON.09.133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A review of the literature demonstrated that clinical evaluation cannot be used to determine 'complete response'. The different classification systems of the histopathologic response grading after neoadjuvant radiochemotherapy of esophageal carcinoma are summarized in this report. A systematic review of studies analyzing preoperative chemoradiation of squamous cell carcinoma (SCC) or adenocarcinoma (AC) of the esophagus demonstrated no significant difference in pathologic complete response (pCR) rates between the AC and SCC studies. Analyzing only the applied dose of radiation demonstrated that patients with AC required a higher dose than patients with SCC to achieve complete response. Incorporating chemotherapy administration does not markedly change the difference in required radiation dose. However, when the tumor does respond, the rate of pCR with increasing dosage of chemoradiotherapy increases more rapidly in AC patients than in SCC patients.
引用
收藏
页码:25 / 35
页数:11
相关论文
共 69 条
[61]  
URBA SG, 1992, CANCER, V69, P285, DOI 10.1002/1097-0142(19920115)69:2<285::AID-CNCR2820690203>3.0.CO
[62]  
2-E
[63]   Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma [J].
Urba, SG ;
Orringer, MB ;
Turrisi, A ;
Iannettoni, M ;
Forastiere, A ;
Strawderman, M .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :305-313
[64]   A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer [J].
Urschel, JD ;
Vasan, H ;
Blewett, CJ .
AMERICAN JOURNAL OF SURGERY, 2002, 183 (03) :274-279
[65]   A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer [J].
Urschel, JD ;
Vasan, H .
AMERICAN JOURNAL OF SURGERY, 2003, 185 (06) :538-543
[66]   A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [J].
Walsh, TN ;
Noonan, N ;
Hollywood, D ;
Kelly, A ;
Keeling, N ;
Hennessy, TPJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (07) :462-467
[67]   Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: A phase I and II study [J].
Wright, CD ;
Wain, JC ;
Lynch, TJ ;
Choi, NC ;
Grossbard, ML ;
Carey, RW ;
Moncure, AC ;
Grillo, HC ;
Mathisen, DJ .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1997, 114 (05) :811-815
[68]   Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: A reliable predictor for patient outcome [J].
Wu, Tsung-Teh ;
Chirieac, Lucian R. ;
Abraham, Susan C. ;
Krasinskas, Alyssa M. ;
Wang, Huamin ;
Rashid, Asif ;
Correa, Arlene M. ;
Hofstetter, Wayne L. ;
Ajani, Jaffer A. ;
Swisher, Stephen G. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (01) :58-64
[69]  
Yonemura Y, 1996, HEPATO-GASTROENTEROL, V43, P1260